61P First-line camrelizumab (Camre) plus carboplatin (Carbo) and pemetrexed (Pem) for advanced non-squamous NSCLC: 5-yr outcomes of CameL phase III study

In the CameL phase III study (NCT03134872), Camre + Carbo-Pem was superior to Carbo-Pem for PFS in patients (pts) with previously untreated, advanced non-squamous NSCLC without EGFR/ALK alterations. Here, we present the updated outcomes after a follow-up of approximately 5 yrs.